Showing results (11-20 of 37) with videos related to
Sort By:
Pageof 4
Methods and Findings in Experimental and Clinical Pharmacology|June 1, 1989
Circulatory counter-regulations induced by continuous administration of nitroglycerinP R Imhof, D Rennwald, P Müller, et al.Journal of Neurochemistry|January 1, 1987
Binding of [3H]Ro 16-6491, a reversible inhibitor of monoamine oxidase type B, to human brain mitochondria and platelet membranesA M Cesura, M D Galva, R Imhof, et al.Lancet (London, England)|January 7, 1989
Controlled trial of transdermal nicotine patch in tobacco withdrawalT Abelin, A Buehler, P Müller, et al.European Journal of Clinical Pharmacology|November 1, 1980
Difference in nitroglycerin dose-response in the venous and arterial bedsP R Imhof, B Ott, P Frankhauser, et al.The Journal of Biological Chemistry|October 9, 2001
The enzymatic and DNA binding activity of PARP-1 are not required for NF-kappa B coactivator functionP O Hassa, M Covic, S Hasan, et al.Methods and Findings in Experimental and Clinical Pharmacology|March 1, 1989
Pharmacokinetics and bioavailability of nicotine in healthy volunteers following single and repeated administration of different doses of transdermal nicotine systemsJ P Dubois, A Sioufi, P Müller, et al.European Journal of Clinical Pharmacology|January 1, 1982
Human pharmacological studies of a new transdermal system containing nitroglycerinP Müller, P R Imhof, F Burkart, et al.Blut|January 20, 1978
Quantitative changes in platelet aggregation due to physiological and pathological factors and medicationT F Rohrer, B Pfister, C Weber, et al.Blut|January 20, 1978
Validity of the Wu-Hoak method for the quantitative determination of platelet aggregation in vivoT F Rohrer, B Pfister, C Weber, et al.European Journal of Clinical Pharmacology|January 1, 1984
Studies of the bioavailability of nitroglycerin from a transdermal therapeutic system (Nitroderm TTS)P R Imhof, T Vuillemin, A Gérardin, et al.Pageof 4